	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	214.10	245.19	518.04	579.29	603.19	438.12	462.68	464.91	411.95	563.18	519.87	522.05	709.26	782.75	886.87
Cost of Operating Revenue	150.59	240.04	408.58	435.37	446.49	338.50	337.31	339.97	294.09	392.34	348.14	411.91	512.22	538.58	623.96
Gross Profit	63.51	5.15	109.46	143.92	156.70	99.62	125.37	124.94	117.85	170.84	171.73	110.14	197.04	244.17	262.91
Gross Margin	29.7	2.1	21.1	24.8	26.0	22.7	27.1	26.9	28.6	30.3	33.0	21.1	27.8	31.2	29.6
Total Operating Expenses	189.12	294.11	473.24	510.17	533.38	382.50	389.20	394.09	354.04	464.34	437.69	499.60	624.15	678.08	755.51
Operating Profit	24.98	-48.92	44.80	69.12	69.81	55.62	73.47	70.83	57.90	98.84	82.18	22.45	85.11	104.67	131.36
Operating Margin	11.7	-20.0	8.6	11.9	11.6	12.7	15.9	15.2	14.1	17.5	15.8	4.3	12.0	13.4	14.8
Financing Income/(Expense) - Net	-23.60	-24.17	-12.29	-1.61	-14.48	-14.75	-14.38	-10.55	-10.06	-10.28	-15.74	-17.26	-19.80	-12.78	-23.08
Profit before Taxes	1.42	29.66	32.02	67.48	56.27	41.58	60.35	62.35	50.76	91.12	68.50	5.35	66.11	92.34	116.64
Income Taxes	0.28	4.34	11.63	32.24	14.63	5.97	19.89	20.90	18.07	30.16	0.62	1.47	16.91	24.94	28.64
Profit after Tax	1.14	25.32	20.38	35.24	40.89	28.49	31.75	40.05	31.57	62.53	62.22	-7.06	49.83	69.14	101.99
PAT Margin	0.5	10.3	3.9	6.1	6.8	6.5	6.9	8.6	7.7	11.1	12.0	-1.4	7.0	8.8	11.5
EPS - Basic - ex Extraordinary Items	0.11	2.53	2.41	4.16	0.48	3.37	3.75	4.73	3.73	7.39	7.35	-0.83	5.89	8.16	11.15
EPS - Diluted - ex Extraordinary Items	0.11	2.53	2.41	4.16	0.48	3.37	3.75	4.73	3.73	7.39	7.35	-0.83	5.89	8.16	11.15
EBIT	24.98	-48.92	44.80	69.12	69.81	55.62	73.47	70.83	57.90	98.84	82.18	22.45	85.11	104.67	131.36
EBITDA	37.62	-35.20	57.66	86.28	89.25	74.80	93.37	90.10	79.97	121.12	114.33	54.58	116.63	139.00	171.28
EBITDA Margin	17.6	-14.4	11.1	14.9	14.8	17.1	20.2	19.4	19.4	21.5	22.0	10.5	16.4	17.8	19.3

Balance Sheet

Abridged

Understanding Balance Sheet

SMS Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	209	227	216	203	136	157	168	208	219	309	377	411	534	554	638
Long-Term Investments	1	1	6	13	20	29	-	-	-	-	-	-	-	-	34
Property Plant & Equipment - Net	273	242	286	306	303	298	287	298	322	463	448	444	465	566	653
Total Non-Current Assets	283	245	294	338	332	336	334	351	389	503	482	469	500	598	724
Total Assets	492	471	509	541	468	493	503	559	608	812	860	880	1,034	1,153	1,362
Total Current Liabilities	171	157	191	166	130	147	121	143	145	194	196	255	332	324	353
Long Term Debt	82	54	69	82	89	74	71	62	73	152	152	122	122	139	172
Total Non-Current Liabilities	100	70	96	121	109	91	97	94	114	208	193	164	166	189	224
Total Liabilities	271	227	287	286	240	238	218	237	260	402	389	419	498	513	577
Total Shareholders' Equity	221	244	222	255	228	255	284	322	348	411	470	461	536	640	786
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total Equity	221	244	222	255	228	255	284	322	348	411	470	461	536	640	786
Total Liabilities & Equity	492	471	509	541	468	493	503	559	608	812	860	880	1,034	1,153	1,362

Cash Flow

Abridged

Understanding Cash Flow Statement

SMS Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	R 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	18.60	-63.08	45.26	98.95	54.05	52.35	70.50	67.95	61.86	96.88	86.00	32.97	83.08	107.60	131.90
Working Capital - Increase/(Decrease)	-9.15	20.21	15.12	-27.72	-1.17	9.40	-48.48	-26.02	-27.60	-12.38	-59.28	-31.29	-54.55	-43.08	-93.99
Net CF from Operating Activities	9.45	-42.87	60.38	71.23	52.88	61.75	22.02	41.93	34.26	84.50	26.72	1.68	28.53	64.52	37.91
Capital Expenditures - Net	-	49.69	53.63	48.13	88.67	23.21	8.55	34.75	42.60	151.62	27.23	29.66	52.07	123.32	130.56
Net CF from Investing Activities	-24.54	98.73	-36.56	-48.13	-96.72	-39.37	-16.62	-34.75	-42.87	-151.78	-27.43	-29.91	-52.23	-123.60	-131.58
Dividends Paid - Cash - Total	1.75	-	1.98	1.98	2.04	2.04	2.04	2.55	5.10	-	2.54	2.54	2.54	3.39	3.55
Stock - Issuance/(Retirement) - Net	-	-	-41.03	-	-	-	-	-	-	-	-	-	28.48	38.09	47.62
Debt - LT & ST - Issuance/(Retirement) - Total	19.88	-48.38	17.68	0.08	37.03	-19.02	-3.02	-2.46	8.46	98.16	9.41	-8.50	26.49	29.73	54.07
Net Cash Flow from Financing Activities	18.13	-48.38	-25.33	-1.90	34.99	-21.06	-5.06	-5.01	3.36	98.16	6.87	-11.04	52.43	64.43	98.15
Free Cash Flow to Equity	29.32	-140.94	24.44	23.19	1.24	19.52	10.45	4.72	0.12	31.05	8.90	-36.48	2.95	-29.07	-38.57
Free Operating CF net dividend	7.70	-93.80	4.75	20.18	-37.94	36.51	11.43	4.54	-13.57	-67.25	-3.07	-30.78	-26.17	-62.24	-96.19
Free Operating CF	9.45	-93.80	6.74	22.16	-35.90	38.55	13.47	7.09	-8.47	-67.25	-0.53	-28.24	-23.63	-58.86	-92.65

Business Segment Analysis

FY End:

Mar 25

SMS Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 123.38 Cr

Revenue / Sales

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 782.75 Cr

Assets

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 1,152.68 Cr

Operating Income

Manufacturing of Active Pharmaceuticals and their intermediates (100.0%)₹ 104.67 Cr

Regional Segment Analysis

FY End:

Mar 25

SMS Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Exports. (69.3%)₹ 542.81 CrDomestic (30.7%)₹ 239.94 Cr

Historical Segment Analysis

Track how SMS Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Manufacturing of Active Pharmaceuticals and their intermediates	43	152	27	30	52	123

Frequently Asked Questions

What is the revenue of SMS Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of SMS Pharmaceuticals Ltd. is ₹ 886.87 Cr, reflecting a 1-year growth of 13.30% and a 3-year CAGR of 19.32%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of SMS Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of SMS Pharmaceuticals Ltd. is ₹ 88.00 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of SMS Pharmaceuticals Ltd.?

The operating margin of SMS Pharmaceuticals Ltd. is -. Detailed EBITDA history is available in the Income Statement section of the Statements tab.

What is the EPS of SMS Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of SMS Pharmaceuticals Ltd. is 9.40. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of SMS Pharmaceuticals Ltd.?

The debt-to-equity ratio of SMS Pharmaceuticals Ltd. stands at 0.46. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of SMS Pharmaceuticals Ltd.?

The estimated book value per share of SMS Pharmaceuticals Ltd. is 83.91 (derived from a P/B ratio of 4.63 and market price of ₹ 388.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of SMS Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of SMS Pharmaceuticals Ltd. is ₹ 37.91 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does SMS Pharmaceuticals Ltd. report consolidated or standalone financials?

SMS Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.